Course Director:
Stephanie Marrus, MA MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF

2019 Advisory Committee:
Tania Fernandez, PhD, President/CEO, Midissia Therapeutics; Founder, Dreamcatcher Ventures
Howard Edelman, CEO, Advanced Resin Therapeutics
Philippe Nore, MSc, MBA, Vice President, Research and Business Development, Adaptive Biotechnologies
Chris Meda, MS, Chief Business Officer, IncellDx
Faz Bashi, MD, Screening Committees, Life Science Angels

Location: UCSF Mission Bay Campus, Genentech Hall N-114. Check schedule, rooms occasionally change.

Dates: January 23 to April 10. Wednesday evenings 5-7:30pm plus three Mondays

Office Hours
Office Hours will be discussed in class. Some are mandatory.

Course Objective
This course is about starting and growing new life science/healthcare (LS/HC) ventures that have the potential to scale to a significant enterprise that can impact human healthcare. Our audience is anyone at UCSF including students, post docs, residents, faculty and staff; graduate students at Berkeley and Stanford; alums from those institutions and the general life science/healthcare business community. We welcome people with diverse backgrounds including MBAs, engineers and computer scientists to augment our scientific/clinical skillset at UCSF. The class is leveled for science/technical/clinical participants with no formal business background.

Startup 101 focuses on the specific characteristics and challenges of a LS/HC venture as distinguished from Tech. We include all types of LS/HC products and services -- therapeutics, medical devices, diagnostics, research tools and digital health.

You will learn how to assess a concept or product in the framework of a business opportunity. This includes assessing whether an idea has market appeal (product/market fit), figuring out a business model, determining the market potential and understanding the key elements of a successful venture. You will learn who your prospective customers are and how to interview them for feedback on your idea. You will understand what is required to access capital and how to source investors who may invest in an early stage company. You will experience the entrepreneurial mindset, solve problems, change plans as you gain more information and develop a network of connections.

Ideas can come from anywhere – from the work you perform, your reading, your knowledge of a field or experience in engaging with the healthcare system as a professional or a patient. You will develop a business plan that includes the key elements required to create a commercial business.
This course will give you the knowledge to create a high-potential, for profit science or medicine-based commercial enterprise. Our emphasis is on ventures that are scalable and can solve important healthcare problems. You may use the skillset you learn here to start a company, join a startup team, innovate within a large company or become an investor. Entrepreneurship research shows that ventures with a team are more successful than solo entrepreneurs. To mirror real life, you will work in a team of 3-5 people on an idea –yours or a classmate’s. If you’re the idea person, you become team lead and must find another 2 people to join you. If you don’t have the idea, you need to find a team lead who invites you. Everyone must be on a team by Week 1.

You will be exposed to entrepreneurs and business professionals. The Advisory Committee, mentors and guest lecturers include serial entrepreneurs, angel investors, venture capitalists, consultants and domain experts who can help you navigate the commercial mindset. LS/HC investors will judge the final presentations.

Objectives and Teaching Methods
The course will help you understand the elements of successful LS/HC ventures, what is involved in doing a startup and the entrepreneurial process. You will hear from entrepreneurs and other members of the business community who share their experiences and knowledge. Students are expected to be highly participative and prepared. The course is experiential, not academic, meaning your team will develop a business plan and pitch deck rather than reading research papers. The class requires that you complete a minimum of 20 interviews for Customer Discovery – testing your value proposition with the marketplace. This is perhaps the most important learning experience you will have and your business plan will suffer without the input.

Guest Speakers
Startup 101 has many invited guest speakers from the Silicon Valley life science business community including entrepreneurs, investors, attorneys and consultants who provide real world experiences and a network for students. These top professionals in their fields provide invaluable perspectives on developing a viable venture.

Major Deliverables: Business Plan Executive Summary and Pitch Deck
During the course, you will develop a business plan for the idea you are working on. The team will research the commercial potential of an idea, test the value proposition, seek product/market fit and create other elements of the plan. Deliverables are a 2-3 page Executive Summary plus a Pitch Deck in the format investors require. There is an opportunity to make a formal pitch for feedback to a group of investors on the final night of class. You will need to submit your product/market fit analysis by Week 3.

Teams
You need to be on a team of 3 to 5 people by the first class. If you form a team around your idea, you are the Team Lead and need to have signed on at least two other people. Every team needs to have at least one UCSF person included.

Some of you are currently working on a venture and have a “real” team outside of class. These people do not qualify as your class team unless they have been accepted. You
must have a Startup 101 team -- people who have applied, been accepted and enrolled. You can continue to work with your real team in the background.

There is sometimes misunderstanding about the role of a class team after Startup 101 is over. Class team members are not automatically founders. The only way you can become a founder is to be invited by the Team Lead.

**Mentors**
Mentorship is an important element for success of a venture. Each team will be assigned an experienced business mentor who is interested in the idea, has relevant expertise and has committed to spend 1-2 hours a week talking with you. Our mentors come from the Silicon Valley business ecosystem and work with or have led startup ventures, lending their expertise in the “pay it forward” culture we are fortunate to have in the Bay Area. They will guide students through business issues that emerge while exploring the idea, support teams in preparing an investor pitch and cheer the team on at the final pitch presentation. You have the opportunity to request a mentor if you believe someone is an especially good fit.

**Time Requirement**
This is a class for people who are motivated to learn by doing. Class is very demanding and requires participation, learning the material and working in a team. By accepting a place in the class, you establish obligations to your team members. You must be serious about the commitment and not become a liability to your team. Be ready to make the commitment and fully engage. Auditing is not permitted.

**Marketplace**
You should input your information on Marketplace even if you have a team assembled. Please go to the Marketplace Input Form: [https://bit.ly/2pt607r](https://bit.ly/2pt607r)
You can see responses on the Marketplace Response Sheet: [https://bit.ly/2PY0C7V](https://bit.ly/2PY0C7V)

**Attendance**
You must come to the first course session to be formally admitted and are expected to attend every session. If you anticipate missing more than one class, please discuss your situation with Leslie Martinez, Program Manager, Entrepreneurship Center.

**UCSF Credit**
UCSF students can receive credit by registering for Biochem 241.

**Fees**
<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current UCSF/UCB students/post docs</td>
<td>0</td>
</tr>
<tr>
<td>UCSF/UCB/Stanford staff or researcher</td>
<td>$400</td>
</tr>
<tr>
<td>Stanford student</td>
<td>$300</td>
</tr>
<tr>
<td>Pre-funding startup</td>
<td>$475</td>
</tr>
<tr>
<td>Funded startup, revenues 0-$5MM</td>
<td>$800</td>
</tr>
<tr>
<td>Corporate, revenues over $5MM</td>
<td>$1200</td>
</tr>
</tbody>
</table>

UCSF/UCB Alumni are not current and must pay normal fees.

**Assigned Book**

**Optional Books**
These books cover different aspects of building a venture.
• Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies, Craig Shimasaki, PhD, MBA. Textbook, relevant for all life sciences sectors
• Technology Ventures: From Idea to Enterprise - Byers, Dorf, Nelson
• Venture Deals: Be Smarter Than Your Lawyer and Venture Capitalist - Feld, Mendelson, Costolo
• The Founder's Dilemma, Wasserman
• Breakthrough Entrepreneurship, Burgstone and Murphy
• The Startup Owner's Manual: The Step-By-Step Guide for Building a Great Company - Blank and Dorf
• Business Model Generation, Alexander Osterwalder
• Do More Faster, Techstars, Cohen and Feld, Available free of charge online. http://library.globalchalet.net/Authors/Startup%20Collection/%5BCohen%20and%20Feld,%202011%5D%20Do%20More%20Faster.pdf
• Biodesign, Zenios, Makower, Yock. The bible for medical devices

Photo and Video Release

By participating in this class, you are giving your consent for photography, filming, videotaping and/or audio recording or other means of capturing my image or voice and/or being quoted in the media or printed materials (including social media websites) at UCSF and hereby authorize release. You are waiving any right to compensation for such uses by reason of the foregoing authorization. Your successors or assigns hereby hold UCSF and its personnel and affiliated programs harmless from any and all liability which may or could arise from activities authorized by this agreement. This authorization expires 12 months after the start of class. Upon expiration of this Authorization, UCSF will not permit further release of any photography or information, but will not be able to call back any photography or information already released.

Class Schedule Overview

<table>
<thead>
<tr>
<th>Class</th>
<th>Date</th>
<th>Day</th>
<th>Topics</th>
<th>Guest Lecturers</th>
<th>Associated Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1/23/19</td>
<td>Wed</td>
<td>Course Intro, Customer Discovery, Opportunity Assessment</td>
<td>Stephanie Marrus, MA MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF</td>
<td>2 minute idea description Finalize teams After class mixer for team networking</td>
</tr>
<tr>
<td>2</td>
<td>1/30/19</td>
<td>Wed</td>
<td>Business Models</td>
<td>Laura Parmer-Lohan, MBA, Founder, Ruckus Partners*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2/6/19</td>
<td>Wed</td>
<td>Networking</td>
<td>Matt Knopf, MBA, SVP Business Development, Tout*</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>--------</td>
<td>-----</td>
<td>------------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2/11/19</td>
<td>Mon</td>
<td>Regulatory</td>
<td>Yarmela Pavlovic, Partner, Hogan Lovells</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early stage funding: SBIR Grants</td>
<td>Errol Arkilic, CEO, M34 Capital; Founding NSF I-Corps Program Director</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Entrepreneur Talk</td>
<td>Caleb Bell, PhD, Founder/CEO, Partner, G4S Capital and Ikigai Accelerator; Cofounder Bell Biosystems*</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2/13/19</td>
<td>Wed</td>
<td>Sector Specific Group Briefing by Advisory Committee</td>
<td>Tania Fernandez, PhD, President/CEO, Midissia Therapeutics; Founder, Dreamcatcher Ventures* Howard Edelman, CEO, Advanced Resin Therapeutics*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Philippe Nore, MSc, MBA, Vice President, Research and Business Development, Adaptive Biotechnologies* Chris Meda, MS, Chief Business Officer, IncellDx* Faz Bashi, MD, Life Science Angels*</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2/20/19</td>
<td>Wed</td>
<td>Reimbursement</td>
<td>Bruce Quinn, MD, PhD, MBA, Principal, Bruce Quinn Associates*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Intellectual Property</td>
<td>Todd Esker, JD, Partner, Morgan Lewis* David Fung, PhD, Senior Licensing Officer, Office of Technology Management, UCSF</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>2/25/19</td>
<td>Mon</td>
<td>Corporate Legal</td>
<td>Alan Mendelson, JD, Partner, Latham &amp; Watkins*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Establishing Corporate Culture and entrepreneur story</td>
<td>Sami Inkinen, MBA, Founder/CEO, Virta Health*</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td>Pitching</td>
<td>Stephanie Marrus, MA MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Day</td>
<td>Event</td>
<td>Speaker(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Wed</td>
<td>Entrepreneur talk and example pitch</td>
<td>Zachary Hill, PhD, CoFounder/CEO, Alex Martinko, CoFounder, Soteria Biotherapeutics*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Wed</td>
<td>Angel and Venture Capital Investors</td>
<td>Allan May, JD, Founder and Chairman, Life Science Angels*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peter Thompson, MD, Partner, Orbimed *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Wed</td>
<td>Team Building</td>
<td>Teresa Toller, Director, Talent Acquisition, Grail*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jeremy Bender, PhD, MBA, VP Corporate Development, Gilead*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Mon</td>
<td>3 minute pitch practice</td>
<td>Stephanie Marrus + others</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Wed</td>
<td>Finance &amp; Budgeting</td>
<td>Sandeep Shroff, MS, MBA, CEO, myStartupCFO *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Build a Budget for first 18 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Wed</td>
<td>Mistakes I Won’t Repeat</td>
<td>Ryan Howard, Founder/CEO, iBeat *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Arvind Gupta, MS, General Partner, SOSV; Founder, IndieBio*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/27/19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Wed</td>
<td>Rehearsal and feedback for Pitch Night</td>
<td>Advisory Committee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Wed</td>
<td>Pitch Night</td>
<td>Investor judges</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Prereadings**

You are expected to complete the pre-readings before the January 23 class. These readings will help you explore whether you have the entrepreneurial personality.

- Meyer/Crane text: Chapter 1, Are You Suited for Entrepreneurship?
Week by Week Schedule
Class is held on Wednesday evenings and occasional Monday nights.

January 23. Course Intro; Opportunity Assessment; Customer Discovery.

Stephanie Marrus, MA MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF, Course Director

Review of the syllabus and course expectations.
How to assess whether your idea is an opportunity. How do you know if anyone wants the product/service you plan to provide? Testing your value proposition. Doing customer discovery, getting unbiased customer feedback. Market information expected by investors. Be prepared to give a 2-minute description of your idea.

Readings:

Meyer/Crane Text:
Chapter 1, Developing an Industry Focus, Conducting a Fast, Effective Industry Analysis and Define the Type of Business you Might Want to Start
Chapter 2, Defining the Target Customer- Users and Buyers
Chapter 3, Defining the Needs of Target Customers- Getting into their Hearts and Minds


After class mixer to complete team recruitment and meet classmates.

January 30th
Business models

Laura Parmer-Lohan, MBA, President and Founder, Rukus Partners

**Networking for Customer Discovery**

**Matt Knopf, MBA, Senior VP Business Development, Tout and Startup 101 alum.**

Learn the process and tools to secure meetings with potential partners and customers. How to find the right people for customer discovery. Getting in the door. How to access places when you aren’t invited in. Maximizing every contact.

Readings:
Meyer/Crane Text:
Chapter 5, Defining the Business Model for a Venture
Chapter 7, Conduct a Reality Check on the Venture Concept and its Business Model
Chapter 11, Writing the Business Plan


Executive summary:

**February 6th**

**Clinical/ Regulatory**

**Yarmela Pavlovic, JD, Partner, Hogan Lovells**


Readings:

FDA clinical research: [https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm](https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm)
Early Stage Funding: SBIR Grants

Errol Arkilic, PhD, CEO, M34 Capital; Founding NSF I-Corps Program Director

Description of the SBIR program. Funding available in Phase 1 and Phase 2. Combined Phase 1,2 grants and direct to Phase 2. How to maximize your chances of getting a grant. Grant review process and success rates. Timelines. The importance of customer discovery in Phase 2 applications.

Readings:

The NIH SBIR process, https://sbir.nih.gov/review/selection-process

Sample Phase 1 SBIR proposals, https://www.niaid.nih.gov/grants-contracts/sample-applications#r43r44

NSF SBIR grants: https://seefund.nsf.gov/about/

Deliverable: 1 page product market fit writeup. What are your assumptions about how your product fits the market need?

Mentor mixer after class. Meet your mentor and other mentors participating in the class.

February 11th. Sector Specific Group Briefing

Therapeutics:
Tania Fernandez, PhD, Founder and Managing Partner, DreamCatcher Ventures: President & CEO, Midissia

Digital Health:
Faz Bashi, MD, Life Science Angels

Medical Devices:
Howard Edelman, CEO, Advanced Resin Therapeutics

Diagnostics:
Philippe Nore, MSc, MBA, Vice President, Research and Business Development, Adaptive Biotechnologies
Chris Meda, MS, Chief Business Officer, IncellDx

Class will break into these four segments and hear a talk by our expert Advisory Board in that sector. They will explain the dynamics of the sector that are different from others, for example, IP, clinical/regulatory, business models, investors.
Readings:

**February 13th.**
**Reimbursement**

Bruce Quinn, MD/PhD, MBA, Principal, Bruce Quinn Associates

Payers and providers defined. How reimbursement works. How do payers think about new technology? What are their criteria for reimbursing and what is the process to be considered? [This is fine to write this way but I think of it as one topic. How important is the patient, the physician, the hospital in the reimbursement decision? How does the formulary decision get made?]

New Trends:
Outcomes based research and how it’s used in making decisions. Comparative effectiveness as a metric. Economics of value based care vs. fee for service.

**Intellectual Property**

David Fung, PhD, Senior Licensing Officer, Office of Technology Management, UCSF

Todd Esker, JD, MS, Partner, Morgan Lewis

When you should think about IP and when to let OTM know about it (for UCSF inventors). Implications of presenting in scientific meetings, poster sessions, publishing. When to file. Types of intellectual property. The importance of patents. IP strategy. Protecting different types of inventions, eg therapeutics, diagnostics, software/digital health. Provisional patents. Freedom to Operate.

Readings:
UCSF Office of Technology Management FAQs, https://innovation.ucsf.edu/office-technology-management-faqs

**February 20th.**
**Corporate Legal**

Alan Mendelson, Partner, Latham & Watkins
Setting up the legal structure for your venture. When to incorporate. Type of corporation to establish. Founders agreement and how to split equity. Other key agreements: confidentiality, invention ownership. Terms in an angel or venture financing round. Legal pitfalls that may make a high valuation deal unattractive.

Readings:


Latham and Watkins legal documents: https://www.lathamdrive.com/resources

Andreesen Horowitz, How Startup Options (and Ownership) Works https://a16z.com/2016/08/24/options-ownership/


Establishing Corporate Culture and an Entrepreneur’s Story

Sami Inkinen, MBA, Founder/CEO, Virta Health

The beliefs and behaviors that determine how a company’s employees and management interact. Implied vs. defined culture. Defining a culture from the start.

Readings:


February 25th.

Pitching and Storytelling
Stephanie Marrus, MA MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF, Course Director

The key slides for an effective pitch. Top investor interests, what makes them tune in or out. Slide by slide detail. Who should present on your team. Designing slides for optimal communication. The power of storytelling. How to manage the meeting and timing. What to expect during and after the meeting. The elevator pitch

Entrepreneur Story and Pitch: Soteria

Zach Hill, PhD and Alex Martinko, PhD, Cofounders, Soteria Biotherapeutics

Readings:
Canaan Partners pitch outline, https://www.slideshare.net/canaanpartners/canaan-pitch-workbook, p 10-26. This is one example, don’t copy it exactly but use it as a model to refer to.

YC Seed Pitch Template, https://docs.google.com/presentation/d/17nFlwCyf2Kz-Ao5HGNmvNZ74L8eSKA2C2Qdaoe-47OM/edit?ts=5aa2fa27#slide=id.g3487a9cbaa_0_27

Founders Institute, How to Nail the Pitch, https://fi.co/insight/how-to-nail-the-pitch-17-storytelling-tips-for-startups


February 27th. Investors

Allan May, JD, Founder and Chairman, Life Science Angels

Peter Thompson, MD, Partner, Orbimed

Presentations by a leading angel investor and a top tier venture capitalist.

What angel investors require and their process to invest. How angels are different than vc’s. Structure of an angel investment. How angels make money. What you need to have to attract angel investment. Angel criteria for investing. Timeframe for exit.

How private venture capital works. Which type of investor is appropriate at what stage. How venture portfolios are constructed and expectations for return. How vc’s access money to make investments from limited partners. Returns needed and timeframe for exit. Valuation. Process for raising a venture round.
Readings:

Meyer/Crane Text: Chapter 8, Financial Sources for Startups and Corporate Ventures


Sequoia Capital, How to Present to Investors, https://www.sequoiacap.com/article/how-to-present-to-investors/ The key slides for an effective pitch. Top investor interests, what makes them tune in or out. Slide by slide detail. Who should present on your team. Designing slides for optimal communication. The power of storytelling. How to manage the meeting and timing. What to expect during and after the meeting. The elevator pitch


Atrium, How to Raise a Seed Round, https://www.atrium.co/blog/seed-stage-funding-startups/


March 6th.

Team Building

Teresa Toller, Director, Talent Acquisition, Grail

How do you find the right team to work with? Who should be founders? How do you divide equity among the founding team? Who should be on the initial team and when do you add people. Why you should strive for balance. How to create a shared vision. Hiring and recruiting. What if someone doesn’t work out? When should you assemble a Board of Directors and an Advisory Board? Who should be on them? Compensation. Leveraging advisors and consultants. When to hire and when to get contract help.

Readings:

Meyer/Crane Text: Chapter 10, Organizing the Venture Team

Founders Workbench, http://www.foundersworkbench.com/. Look around the site for good nuts & bolts information. Specific to team building:
Naval, How to Pick a Cofounder, VentureHacks, http://venturehacks.com/articles/pick-cofounder


Kauffman Foundation, Surprising Facts from The Founder’s Dilemmas: Anticipating and Avoiding the Pitfalls that can sink a Startup, https://www.kauffman.org/~/media/kauffman_org/resources/books/founders_dilemmas_surprising_facts


**Business Development/Partnering**

**Jeremy Bender, PhD, MBA, VP Corporate Development, Gilead**

Industry trends for partnering. Partnering with a Pharma, what’s the right time for an early stage company. The right entry point into the organization, key influencers. What the partner needs from a deal. How Pharma assesses the asset, the process to decide to partner and how value is set. Typical deal structure. Pitfalls. When you should consider merger or acquisition instead of partnership. IPOs.

**Readings:**


Shomit Ghose, The Key to a Good M&A Outcome for your Startup: Getting Started Yesterday, http://scet.berkeley.edu/key-good-ma-outcome-start-getting-started-yesterday/
March 11th. Pitch Practice

Present the first three minutes of the pitch – problem, solution, opportunity -- and get feedback.

Readings:
Meyer/Crane Text: Chapter 12, Making the Pitch


March 13th. Finance

Sandeep Shroff, MS MBA, Co-Founder and CEO, myStartupCFO

Financial metrics the management team needs to focus on. The key financial statements. What data goes into them? The importance of cash. The difference between corporate finance and entrepreneurial finance. How to know if you have enough cash and when you’ll run out. Creating a budget. How to manage to a budget. Breakeven. Entrepreneurial finance. The financial metrics you need to focus on in a startup venture. Translating your business model into financial projections. Understanding cash flow. Projecting revenues and expenses. Estimating startup costs and capital expenditures.

Readings:
Meyer/Crane Text: Chapter 11, Financial Projection


Richards, How to do a breakeven analysis, http://entrepreneurs.about.com/od/businessplan/a/breakeven.htm

March 20th. Mistakes I Won’t Repeat

Ryan Howard, Founder, CEO, iBeat

Mistakes not to make as a founder. Lessons Learned and how to do it right.

Readings:
**Next Steps: Accelerators**

Arvind Gupta, MS, General Partner, SOSV; Founder, IndieBio

**March 27th. No class**

**April 3rd. Pitch Rehearsal**

This is the chance to test out your pitch and get feedback before Investor Pitch Night. If we have too many teams for the evening, we will hold a competition for you to secure a slot.

**April 10th. Investor Pitch Night**

Investors and other interested parties will convene in Mission Bay to hear the results of Startup 101 teams.

**Course Leadership Biographies:**

**Course Director:**

Stephanie Marrus, MA, MBA, Director, Entrepreneurship Center and Senior Lecturer, UCSF

Ms. Marrus is responsible for delivering programs and courses enabling scientists and clinicians to create entrepreneurial ventures based on UCSF technologies. She leverages her participation in the Silicon Valley ecosystem to attract resources and entrepreneurship thought leadership to Campus. During a 25-year plus career, she has been involved as a corporate executive, business consultant and mentor with hundreds of companies in science- and technology-based industries, many with their technological roots at MIT, Harvard, the University of California and Stanford. Her consulting clients have included venture capitalists, CEOs, National Science Foundation grantees and foreign government entities. She serves the NIH as an SBIR reviewer.

In addition to her business career, she served as Deputy Secretary of Economic Affairs for a Massachusetts governor where she took the lead on economic development and business policy and has consulted to the White House on entrepreneurship policy. She has been President of a medical research foundation and served on the Advisory Board of a social venture startup accelerator.

She has taught on five continents and is part of the US State Department International Speaker Program. Locally, she has been a guest lecturer at Stanford University and UC Berkeley. Her academic titles have included Faculty at UC Berkeley Center for Entrepreneurship in Technology (SCET), Entrepreneur-in-Residence at the Haas School of Business, UC Berkeley; Adjunct Professor, St. Petersburg State University Graduate School.
of Management, Russia; and Entrepreneur-in-Residence, King Abdullah University of Science and Technology, Jeddah, Saudi Arabia.

She holds an MBA from the Wharton School, University of Pennsylvania, a MA from Columbia University and an AB from Cornell University.

Advisory Committee

Tania Fernandez, PhD, President and Chief Executive Officer, Midissia Therapeutics; Founder, DreamCatcher Ventures

With over 2 decades of in-depth experience in the life sciences and over 10 years of venture investing, Dr. Fernandez’s expertise encompasses scientific and medical research, venture capital, finance and entrepreneurship. She is President & CEO of Midissia Therapeutics, a clinical stage immunotherapy start-up whose mission is to develop therapeutic personalized cancer vaccines to significantly impact the overarching problems of toxicity, drug resistance and recurrence that plague current modalities of cancer treatment. Midissia is the recent recipient of the Immunomics Cancer Discovery Incubator Award.

She is also the Founder of DreamCatcher Ventures, a strategic advisory services firm that specializes in working with entrepreneurs to create, build and scale businesses effectively through a scientific and commercial analysis of technologies/products, refining of business models, competitive analysis, corporate strategy, and market intelligence. She serves as a Principal Advisor to Larta on the NIH Commercialization Assistance Program.

Dr. Fernandez is currently on the Boards of Midissia, Modularix and on the Editorial Board of the Interdisciplinary Journal of Applied and Biomedical Sciences. Dr. Fernandez secured her doctorate at the Cancer Research Institute, India, having been awarded the Indo-US scholarship from the National Institutes of Health (NIH), USA. Her research work won her the Young Scientist Award She was also awarted the most outstanding doctoral thesis award at Bombay University. Her postdoctoral work at the National Cancer Institute, NIH resulted in two awards for excellence in biomedical research. She completed her post-doctoral training in protein chemistry and genetic engineering at the College of Medicine, Texas A&M University. She previously gained operational experience at Hoechst Pharma. Dr. Fernandez works extensively with entrepreneurs and has been/is an instructor/mentor/investor coach/judge to UCSF, UC Davis, Harvard University and Berkeley.

Howard Edelman, CEO, Advanced Resin Therapeutics

As a Senior Operations and Product Development Executive, Howard Edelman has a record of success in generating multimillion dollar outcomes within medical device, medical equipment and orthopedic markets. He is known for his expertise in operations, product development, marketing and sales within startup organizations and global entities, having founded and led several organizations to profitability. Howard’s experience includes multi-
market, multi-disciplined technical environments focusing on innovation, product development, market strategy, all phases of execution, operations, global supply chain development and management, manufacturing lifecycle, marketing and sales development. Mr. Edelman has over 25 years of leadership in engineering and operations management, design, and development primarily in medical devices and scientific instrumentation and has brought to market +25 medical and scientific instruments throughout the course of his career generating more than $250M in revenue.

Mr. Edelman currently serves as CEO of Advanced Resin Therapeutics, formerly CEO of WI-MM, Founder and CEO of VitalWear, Inc., and has served in management roles in firms such as Cothera LLC, Johnson & Johnson, Zeiss, CooperVision, and Bio-Rad Laboratories and various startup companies in the Bay Area. Mr. Edelman presently sits on the Research Committee for the Juvenile Diabetes Research Foundation and assists a number of early stage medical device companies. Mr. Edelman graduated from Boston University in 1983 with a B.S. in Biomedical Engineering.

Philippe Nore, MSc, MBA, Vice President, Research and Business Development, Adaptive Biotechnologies

Philippe Nore is an experienced executive specialized in clinical diagnostics, genomics and life science tools. He has extensive US and international experience and a demonstrated track record of developing and launching new businesses. Prior to joining Adaptive, he founded a medtech diagnostics company MiNDERA and was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the products in the cancer diagnostics market, including global P&L responsibility.

Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. He worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business unit and led the Next-Generation Sequencing taskforce. He also spent seven years at Bain & Company where he consulted for Fortune 500 companies. Mr. Nore holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.

Chris Meda, MS, Chief Business Officer, IncellDx

Ms. Meda is an experienced biotech CEO, President, CBO, and COO within private and public pharmaceutical and medical diagnostics companies, as well as an experienced board member. She is Chief Business Officer at IncellDx, a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. Ms. Meda has 30 years of leadership in the diagnostic and pharmaceutical industries. Her management responsibilities have included the creation of strategic business direction and plans, operations and
commercialization of more than 30 products for various disease areas at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics and Schering AG pharmaceuticals. She is Chair of Women in BIO- San Francisco Chapter, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and, a Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. She was President of Response Genetics, a personalized medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers which help medical oncologists with therapeutic treatment decisions for patients with these cancer types. Prior to RGI, she was CEO, President at Arcxis Biotechnologies, a venture backed start-up with a focus on molecular diagnostic extraction devices and reagents. She was Vice President at Hoffman-LaRoche, Roche Molecular Diagnostics Division for the Global Women’s Health Portfolio and subsequently became Vice President of Business Development. Her leadership role and portfolio duties included strategic planning for the portfolio, oversight of research and development and the commercialization of PCR-based diagnostics. Her business development role was focused on companion diagnostics where she completed agreements between Roche Molecular Diagnostics and four pharmaceutical companies.

**Faz Bashi, MD, Life Science Angels**

Faz has a research background in Immunology and Virology from UCSF. He has been Chair of the Angel Capital Association's Life Sciences Syndication group and Chair of the Life Science Angels (LSA) Device Screening Committee, active member of the LSA Biotechnology & Pharmaceuticals Screening Committee. He is a founding member of HealthTech Capital where he served on the Board of Directors for a 2 year term. He is a member of Berkeley Angel Network. He has been active as a mentor with Pacific Community Ventures, which creates jobs and economic opportunity by increasing investment in local businesses. He also volunteers with UCSF’s CTSI external advisory board and Springboard Enterprises. Faz worked at San Mateo Medical Center to develop and implement special clinical projects to help the underserved, including TeleDermatology, Diabetic Retinopathy Screening, and advancements in electronic medical records. He works as a consultant to Patient Visit Redesign as a Deep Dive expert, and he coaches on workflow process improvement for public health clinics, community health centers, and safety net organizations across the US.